RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:391

Classic Hodgkin lymphoma

high confidenceDisorder

Also known as: Classic Hodgkin disease

Publications

8,425

95.7th percentile

Trials

157

Interventional, condition-specific

Researchers

1,402

Distinct authors in sample

Gene link

KLHDC8B

Limited

Readiness

5/6

Stages with a signal

Clinical definition (Orphanet)

Classical Hodgkin lymphoma (CHL) is a B-cell lymphoma characterized histologically by the presence of large mononuclear Hodgkin cells and multinucleated Reed-Sternberg (HRS) cells.

How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (3)

classic Hodgkin disease · classical Hodgkin lymphoma · classical Hodgkin's lymphoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

5/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Limited — KLHDC8B

  2. LiteraturePresent

    8,425 matched papers (6,335 in last 10 years) Source

  3. Phenotype characterisedPresent

    35 HPO annotations (e.g. Lymphoma; Lymphadenopathy; Cellular immunodeficiency) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPresent

    7 FDA designations (4 FDA orphan-indication approvals) — e.g. (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one Source

  6. Interventional trialPresent

    157 matched on ClinicalTrials.gov (33 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Possibly — only limited evidence so far for KLHDC8B.

GenCC classification: Limited.

Phenotypes (Monarch / HPO)

35

Associated phenotypes · MONDO:0009348

  • Lymphoma
  • Lymphadenopathy
  • Cellular immunodeficiency
  • Fatigue
  • Hyperhidrosis

Showing 5 of 35 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

7

Designations · 4 with FDA orphan-indication approval

  • FDA (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-oneHodgkin Lymphoma · 2015-04-29 · Not FDA Approved for Orphan Indication
  • FDA resminostathodgkin's lymphoma · 2011-09-16 · Not FDA Approved for Orphan Indication
  • FDA panobinostathodgkin's lymphoma · 2009-09-18 · Not FDA Approved for Orphan Indication
  • FDA Prednimustinehodgkin's lymphomas · 1985-06-17 · Not FDA Approved for Orphan Indication
  • FDA pembrolizumab (KEYTRUDA)Hodgkin Lymphoma · 2015-12-30
  • FDA nivolumab (OPDIVO)Hodgkin Lymphoma · 2014-08-07
  • FDA brentuximab vedotin (Adcetris)hodgkin's lymphoma · 2007-01-30

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

90

Drugs / clinical candidates · MONDO_0009348

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

8,425

8,425 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

8,425 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

6,335 in the last 10 years · high confidence · 95.7th percentile (publications denominator)

Phrase hits: 8,246 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,402

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Molin D6 papers · 2026

    Department of Immunology, Genetics, and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala Akademiska Hospital, Uppsala, Sweden.

    Papers in Europe PMC
  2. 02
    Wang L6 papers · 2026

    Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

    Papers in Europe PMC
  3. 03
    Armand P5 papers · 2026

    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

    Papers in Europe PMC
  4. 04
    Kamper P5 papers · 2026

    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark.

    Papers in Europe PMC
  5. 05
    Liu C5 papers · 2026

    Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

    Papers in Europe PMC
  6. 06
    Liu Y5 papers · 2026

    Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

    Papers in Europe PMC
  7. 07
    Ansell SM4 papers · 2026

    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN. Electronic address: Ansell.Stephen@mayo.edu.

    Papers in Europe PMC
  8. 08
    Herrera AF4 papers · 2026

    Department of Hematology and Department of Oncology, Duarte, California, USA.

    Papers in Europe PMC
  9. 09
    Kuruvilla J4 papers · 2026

    Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada. Electronic address: john.kuruvilla@uhn.ca.

    Papers in Europe PMC
  10. 10
    Li Z4 papers · 2026

    Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. lixixi616@sina.com.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

157

interventional trials for this specific condition

157 interventional trials matched this specific condition name; 33 currently recruiting in our sample.

Data as of 11 September 2026 · last trial check 28 July 2026

157 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.1th percentile).

high confidence · 99.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

157 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

17 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 32 · after dedupe 32 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 32 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (32)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Classic Hodgkin lymphoma — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Classic Hodgkin lymphoma" OR "Classic Hodgkin disease" OR "classical Hodgkin lymphoma" OR "classical Hodgkin's lymphoma") OR ("KLHDC8B" OR "KLHDC8B syndrome" OR "KLHDC8B-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Classic Hodgkin lymphoma" OR "Classic Hodgkin disease" OR "classical Hodgkin lymphoma" OR "classical Hodgkin's lymphoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 157 interventional · 17 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T13:40:51.225Z